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Introduction
Melanoma, the most serious type of skin cancer, 
develops in the melanocytes which can form in eyes and, 
rarely in internal organs, such as intestines (Jerant et al., 
2000; Lens and Dawes, 2004; Parkin et al., 2005; Narin 
and Tuncay, 2012). The incidence and mortality rate of 
the melanoma have been increased during recent years 
(Lens and Dawes, 2004; Cihan et al., 2013). It has been 
estimated that approximately, fifty thousand melanoma 
related deaths occur worldwide yearly (Jerant et al., 2000; 
Parkin et al., 2005; Kanavy and Gerstenblith, 2011). It is 
more common in female, which is mainly presented in 
the legs that differ to male individuals where the back is 
the most common site of involvement (Jerant et al., 2000; 
Parkin et al., 2005; Kanavy and Gerstenblith, 2011).
The geographic pattern of disease indicates the 
principal cause is ultraviolet (UV) exposure; however, 
the exact cause of all melanomas is not clear (Kanavy 
and Gerstenblith, 2011). HER-2/neu proto-oncogene is 
initially isolated from a human mammary carcinoma and 
a salivary gland adenocarcinoma. HER-2/ neu oncogene 
encodes a 185 kDa cell surface glycoprotein and shows 
intrinsic tyrosine kinase activity that regulates cell growth 
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Abstract
 Background: This study was performed to evaluate the amplification of HER-2/neu in patients with melanoma. 
Materials and Methods: Amplification of HER-2/neu was evaluated in a group of patients with melanoma, referred 
to two referral centers in Tehran, using immunohistochemistry (IHC) and chromogenic in situ hybridization 
(CISH) techniques. Results: Forty patients with mean age 57.9±19.5 years were enrolled in this study. The most 
frequent type of melanoma was acral, while lower limbs were the most frequent sites. The amplification of HER2/
neu was negative in 97.5% of patients with IHC and in 100% of patients with CISH technique. Only one case 
(2.5%) shows weak positive staining (+2) in IHC method. Fifty five percent of melanoma was ulcerative, and the 
most common stages of tumors were stages 4b and 3b. More than 47% of cases were in Clark level III, while the 
mean of Breslow thickness was 3.56±2.87 mm. The stage of the case that showed weakly positive staining (2+) in 
IHC was 4b. Conclusions: The amplification of HER2/neu biomarker was negative in patients with melanoma, 
using both CISH and IHC techniques. 
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and differentiation (Ullrich and Schlessinger, 1990). 
HER-2 is a member of epidermal growth factor (EGF) 
receptor family and amplification or overexpression of 
this oncogene has been shown to play an important role 
in the development and progression of certain aggressive 
types of malignancy including ovarian, lung, gastric, 
endometrial and glioblastomas (Hetzel et al., 1992; 
Hiesiger et al., 1993; Tsugawa et al., 1993; Yu et al., 1994; 
Easty et al., 1995). The studies in this field are limited and 
the extent to which HER-2/neu is amplified in melanomas 
is not well known (Rongcun et al., 1999). During recent 
years, the HER-2/neu has become as an important 
biomarker and target of therapy for breast cancer. The 
verification of overexpression of HER-2/neu in patients 
with melanoma would be a remarkable scientific progress 
in understanding of melanogenesis and may feasibly lead 
to the diagnosis in early stage and effective treatment (Potti 
et al., 2004). The studies have confirmed HER2 expression 
with the HercepTestTM (DAKO) immunohistochemical 
(IHC) assay for evaluation of HER2 expression in breast 
cancer. Moreover these studies indicated that CISH is a 
useful alternative for detection of HER2 amplification in 
tumor samples, especially for confirming the IHC staining 
results (Tanner et al., 2000). Therefore, to shed light to the 
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over expression of HER-2/neu in patients with melanoma, 
this study was performed to evaluate the amplification of 
HER2/neu, using IHC and CISH techniques.
Materials and Methods
Study design 
In this cross sectional study, 40 patients with melanoma 
who were referred to the Rasoul-e-Akram General 
Hospital and the Razi Dermatology Hospitals during 2006-
2011 were recruited. The patients’ information, including 
age, sex, tumor type, site, stage, thickness and depth of the 
tumor were recorded. Then the samples were evaluated 
to select the best section of the tumor for IHC and CISH. 
To evaluate the amplification of HER2/neu, 40 paraffin 
blocks were retrieved from archive of pathology wards 
and one cut (4-6 mm) for IHC and 2 cuts (3 mm) for CISH 
were selected from each block. IHC was performed in the 
Rasoul-e-Akram pathology laboratory (EnVision method) 
and CISH in the Oncopathology Research Center of Iran 
University of Medical Sciences.
IHC method
Immunohistochemical staining was performed on 4-5 
μm thick FFPE tissue sections mounted on poly-l-lysine 
pre-coated slides using EnVision method (Gheytanchi 
et al., 2014). Sections were deparaffinized, using xylene 
and alcohol 100o and 96o and stained, using rabbit anti 
human HER2 polyclonal antibody (Code: A0485Dako, 
Copenhagen, Denmark). Heat-induced antigen retrieval 
was applied, using autoclave method and DAKO target 
retrieval solution. After washing with phosphate buffer 
saline (PBS), specimens were incubated with antibodies 
for 90 min at room temperature. Then, samples were 
incubated for 45 min with DAKO EnVision system at room 
temperature. Visualization of the reaction was acquired 
using diaminobenzidine (DAB) solution. Staining with 
Mayer’s hematoxylin was performed afterwards. At each 
staining session, HER2 positive breast invasive ductal 
carcinoma was used as positive controls, and negative 
controls were prepared through elimination of antibody. 
Then the slides were observed by light microscope. The 
slides were scored based on ASCO/CAP criteria.
IHC evaluation and scoring
The immune-positivity for HER-2/neu was appeared 
as membranous reaction and sometimes cytoplasmic. 
The positivity of the immunostaining was determined in 
10 different fields at 400 x magnification and recorded as 
negative (score 0 and 1+), weakly positive (score 2+), and 
positive (score 3+) in more than 30% of the tumor cells.
CISH procedure
CISH was performed based on ZytoDot 2C SPEC 
HER2/CEN 17 Probe kit (Mayr et al., 2009; Hwang et 
al., 2011; Gleeson et al., 2014), using in vitro diagnostic 
medical device (IVD) and CE Mark EV directive 98/79/
EC. The PD12 contains two polynucleotide probes. The 
presence of certain nucleic acid sequences in cells or 
tissue can be detected by in situ hybridization, using 
labeled DNA probes. The hybridization results in duplex 
formation of sequences present in the test object with 
the labeled DNA probe. Duplex formation of the labeled 
probe (with sequences of HER2 and chromosome 17 
alpha-satellites in the test material) can be visualized 
using primary (unmarked) antibodies, which are detected 
by secondary polymerized enzyme-conjugated antibodies. 
The enzymatic reactions of chromogenic substrates lead 
to the formation of colored signals that can be visualized 
by light microscope. The polynucleotides contained in 
the ZytoDot 2C SPEC HER2/CEN 17Probe EmaNOF, 
which recognize the alpha-satellite-sequences of the 
centromere of chromosome 17 function in themselves 
as an internal control that a successful hybridization has 
occurred, as well as proving the integrity of the cellular 
DNA. Then the Anti-DIG/Anti-DNP-MIX (AB3) solution 
was added as initial antibody and then recognized by anti- 
bodies containing conjugated polymerase enzyme. Then 
colored solutions were added and red and green signals 
are detectable by light microscope at ×100. These steps 
occurred during 2-4 days as follow:
Step I. Preparatory step (first and second day)
Step II. Pretreatment step including heating and 
incubation in xylene, ethanol, H2O2 (3%) and EDTA
In this step the pretreatment solution (PT2) was heated, 
digested using pepsin Solution (ES1,3-10 minutes) and 
dehydrated using alcohol.
Step III. Hybridization (PD12) and incubation in 37oC 
for one night
Step IV: post hybridization including washing, final 
staining and observing under light microscope
Under light microscope at power 100 the signals of 
hybridization of copy of HER2 was seen as green spot 
signal while the signals of hybridization of chromosome 
17 is seen as a red spot signal that it is differentiated from 
context (blue H,E).
The prepared slides were observed by two pathologists 
based on ASCO/CAP grading guideline. 
The stained slides (IHC method) were interpreted 
using Hercep test as follow: Negative (Score 0 or Score 
1+) *Score 0: No staining is observed or membrane 
staining is observed in less than 10% of the tumor cells; 
*Score 1+: A faint/barely perceptible membrane stain is 
detected in more than 10% of the tumor cells; The cells 
are only stained in part of their membrane
Weakly positive (Score 2+) *Score 2+: A weak to 
moderate complete membrane staining is observed in 
more than 10% of the tumor cells; Strongly positive (Score 
3+); *Score 3+: A strong complete membrane staining is 
observed in more than 10% of the tumor cells
The stained slides (CISH method) were interpreted using 
ASCO/CAP as follow:
Under light microscope at 1000 ×, HER2 signals 
in nuclei were counted and the amplification gene was 
identified. If spots were lower than 6, the gene was 
considered unamplified and amplification was defined 
when the spots ≥6 in more than 50% of cancer cells or a 
small cluster copy of gene (amplified) was present.
If the sample was homogenous at least 30 cancer 
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cells from each sample were recruited but if the sample 
contains 5-10 copy of HER2 gene in less than 50% of 
selected area, at least 60 cancer cells from each sample 
were evaluated. Furthermore, the number of cancer cells 
and ability to detect of the normal copy of HER2 gene 
ratio was measured.
The Zytovision test has green probe for HER2 gene 
and red probe for chromosome 17. These probes were 
recorded in invasive tumor in area that at least had 20 
cells; also uncounted areas were less than 25% and were 
calculated as follow:
HER2/CEP17 <1.8= negative
HER2/CEP17 1.8-2.2= equivocal
HER2/CEP17 >2.2 = positive
Statistical analysis
Data were analyzed using Statistical Package for 
Social Studies version 21 (SPSS Inc, Chicago, Ill). 
Categorical data are presented as numbers (%), and 
continuous data as mean ± SD. We used Chi square test 
to compare categorical variables. P value of less than 0.05 
was considered significant.
Results 
Forty patients, including 19 male (47.5%) and 21 
female (52.5%), with mean age of 57.9±19.51 (range: 
10-89) years were evaluated. The most common type of 
melanoma was acral type, followed by nodular and lentigo 
maligna melanoma, whereas the most common site was 
lower limb that in 22 patients (55%) was ulcerative (Table 
1). Majority of tumors were in stage 4b (25%), followed 
by 1a (20%). Regarding amplification of HER2/neu in IHC 
technique, 39 patients (97.5%) showed negative (Figure 
1) amplification (score 0 and 1+), while one patient was 
weekly positive (score 2+, Figure 2); however, in CISH 
technique, the amplification in all samples were negative 
(Table 1, Figure 3). The stage of one tumor that showed 
Figure 1. Negative Immunoreactivity for HER2/neu 
(Immunohistochemistry), Magnification (40x)
Figure 2. Weak Positive (2+) Staining of one case by 
Immunohistochemistry, Magnification (20x)
Figure 3. No Amplication of HER2/neu by Chromogenic 
in Situ Hybridization (CISH), Magnification (100x)
Table 1. Clinicopathological Characteristics of 
Melanoma Patients
Age <20 1(2.5%)
 20-39 5(12.5%)
 40-59 12(30%)
 60-80 18(45%)
 >80 4(10%)
Melanoma subtypes Acral 21(52.5%)
 nodular 7(17.5%)
 lentigo 7(17.5%)
 superficial 3(7.5%)
 nevoid 2(5%)
Location Lower limb 22(55%)
 Head and neck 11(27.5%)
 trunk 4(10%)
 Upper limb 3(7.5%)
Ulcer  Presence   22(55%)
Tumor staging 1a 8(20%)
 1b 1(2.5%)
 2a 1(2.5%)
 2b 1(2.5%)
 3a 5(12.5%)
 3b 9(22.5%)
 4a 4(10%)
 4b 10(25%)
IHC Score 0 30(75%)
 Score 1+ 9(22.5%)
 Score 2+ 1(2.5%)
Clark level I 1(2.5%)
 II 5(125%)
 III 20(50%)
 IV 8(20%)
 V 5(7.5%)
Breslow Thickness (mm) <0.7 4(10%)
 0.8-1.6 6(15%)
 1.7-3.6 13(32.5%)
 >3.6 16(40%)
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overexpression in IHC was 4b. Mean of Breslow thickness 
was 3.56±2.87 (range: 0.5-15 mm); the most common 
Clark level of sample was III (Table 1).
Discussion
Overexpression of the HER2 protein generally 
results from HER2 gene amplification (Pauletti et al., 
1996). Some studies signified HER-2/neu as a prognostic 
predictive factor in several cancers, such as breast 
cancer, ovarian, non-small cell lung, and gastric cancer 
(Gershenson et al., 1996; Allgayer et al., 2000; Bar-Sela 
et al., 2003). In this study, we evaluated HER2/neu gene 
amplification in 40 patients with cutaneous melanoma 
and obtained similar results with two techniques IHC and 
CISH (97.5% and 100% negative, respectively). Only 
one patient in IHC technique showed weakly positive 
immune staining (2+); however, in CISH technique, the 
amplification in all samples was negative. In other word, 
97.5% of samples were negative in this study that was in 
line with Potti et al study (Potti et al., 2003) that signified 
0.9% of melanoma showed HER-2/neu overexpression by 
immunohistochemistry. Another trial in agreement with 
these findings conducted by El-Shaikh et al that showed 
negative HER2/neu overexpression in more than 90% of 
their patients (El-Sheikh S, 2009). Furthermore, another 
experience in line with our findings conducted by Easty 
et al indicated variable levels of HER-2/neu mRNA in 
19 melanoma cell lines (Easty et al., 1995). Moreover, in 
a study in 16 additional melanoma cell lines, Chenevix-
Trench et al signified low level of HER-2/neu mRNA 
(Chenevix-Trench et al., 1990). However, in contrast to 
our findings and mentioned studies above, Persons et al 
signified that HER-2/neu is amplified in up to 13.16% of 
melanomas (Persons et al., 2000). Bodey et al applied 
immunohistochemistry technique and reported that HER-
2/neu expressed in 40% of primary cutaneous melanoma 
(Bodey et al., 1997). The reason for such discrepancy is 
not clear, but it may be related to difference in patients’ 
selection, study design and staining technique and 
different interpretation of the slides. On the other hand, 
some studies revealed HER2 overexpression in normal 
skin tissue and non-melanoma cancer (Krahn et al., 2001). 
Therefore, HER-2/neu overexpression is not specific for 
melanoma and it appears to have no value as a biomarker 
in patients with skin melanoma.
In this study, the frequency of melanoma in female 
was slightly more than male and the mean age was 57 
years. Conversely, the results observed by Demierre et al 
mentioned melanoma is more common in males, but in 
agreement with findings of this study, it is more common 
after fifty (Demierre et al., 2005). El-Sheikh et al in another 
study reported similar results with Demierre et al in age 
and sex distribution (El-Sheikh, 2009).
The most common type of melanoma in this work was 
acral followed by nodular and lentigo maligna type that 
was in line with Demierre et al study that found nodular 
melanoma is the second most common type of cutaneous 
melanoma; however, in their survey, the most common 
type was superficial spreading type (Demierre et al., 2005). 
In the El-Sheikh et al study (2009), the type of melanoma 
in all patients was nodular.
The most common site of melanoma in present study 
was lower limb, followed by head and neck, conversely 
in the Elshaikh et al study the most common site was face 
and forearm, regarding this fact some studies declare the 
site of the melanoma may be related to prognosis (Levi 
et al., 1998), but is not consistent with other experiences 
that have not shown any correlation (Hoersch et al., 2006).
The most of samples in current survey were in Clark 
level III moreover Breslow thickness in most of the 
samples was more than 3.6 mm. Conversely, in a study 
by Safaie on 47 patients with melanoma, more than 42% 
of cases were in Clark level I, and in 53% of patients, 
Breslow thickness was equal to or less than 0.75 millimeter 
(Safaie-Naraghi et al., 2006). The melanoma in 55% of 
our patients was ulcerative and the most of tumors were 
in stage 4b (25%). Moreover the stage of one tumor that 
showed overexpression in IHC was 4b.
It could be suggested that the amplification of HER2/
neu biomarker was negative in patients with melanoma, 
using both CISH and IHC techniques. However, any 
conclusion from this study is limited by low number of 
enrolled cases, which is consistent with previous studies 
in this field as well.
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